Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells

Journal of Pineal Research

Volumn 53, Issue 1, 2012, Pages 77-90

  Wang, Jingshu ^a   Xiao, Xiangsheng ^a   Zhang, Yun ^a   Shi, Dingbo ^a   Chen, Wangbing ^a   Fu, Lingyi ^a   Liu, Liqun ^c   Xie, Fangyun ^a   Kang, Tiebang ^a   Huang, Wenlin ^a,b   Deng, Wuguo ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b State Key Laboratory of Targeted Drug for Tumors of Guangzhou Double Bioproduct Inc   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Akt; Apaf 1; Breast cancer; COX 2; Melatonin; p300

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE 3; CASPASE 9; CYCLOOXYGENASE 2; CYTOCHROME C; GLYCOGEN SYNTHASE KINASE 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MELATONIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN E2; PROTEIN KINASE B; PROTEIN P300; SMALL INTERFERING RNA;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG SCREENING; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SECRETION; RNA INTERFERENCE;

ANTIOXIDANTS; APOPTOSIS; APOPTOTIC PROTEASE-ACTIVATING FACTOR 1; BREAST NEOPLASMS; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE 2; DINOPROSTONE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELATONIN; P300-CBP TRANSCRIPTION FACTORS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84863602663     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2012.00973.x     Document Type: Article

References (58)

1. Reeder-Hayes KE, Carey LA, Sikov WM. Clinical trials in triple negative breast cancer. Breast Dis 2010; 32:123-136.
2. van Agthoven AT, Sieuwerts AM, Meijer-van Gelder ME et al. Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. J Clin Oncol 2009; 27:542-549.
3. Mohanraj L, Oh Y. Targeting IGF-I, IGFBPs and IGF-I receptor system in cancer: the current and future in breast cancer therapy. Recent Pat Anticancer Drug Discov 2011; 6:166-177.
4. Tagliabue E, Balsari A, Campiglio M et al. HER2 as a target for breast cancer therapy. Expert Opin Biol Ther 2010; 10:711-724.
5. Alvarez RH. Present and future evolution of advanced breast cancer therapy. Breast Cancer Res 2010; 12(Suppl 2):S1.
6. Lord S, Harris AL. Angiogenesis -still a worthwhile target for breast cancer therapy? Breast Cancer Res 2010; 12(Suppl 4):S19.
7. Itez-King G. Melatonin as a cytoskeletal modulator: implications for cell physiology and disease. J Pineal Res 2006; 40:1-9.
8. Lee YD, Kim JY, Lee KH et al. Melatonin attenuates lipopolysaccharide- induced acute lung inflammation in sleepdeprived mice. J Pineal Res 2009; 46:53-57.
9. Guney Y, Hicsonmez A, Uluoglu C et al. Melatonin prevents inflammation and oxidative stress caused by abdominopelvic and total body irradiation of rat small intestine. Braz J Med Biol Res 2007; 40:1305-1314.
10. Dominguez-Rodriguez A, Breu-Gonzalez P. Melatonin: still a forgotten antioxidant. Int J Cardiol 2011; 149:382.
11. Korkmaz A, Reiter RJ, Topal T et al. Melatonin: an established antioxidant worthy of use in clinical trials. Mol Med 2009; 15:43-50.
12. Galano A, Tan DX, Reiter RJ. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res 2011; 51:1-16.
13. Bonnefont-Rousselot D, Collin F, Jore D et al. Reaction mechanism of melatonin oxidation by reactive oxygen species in vitro. J Pineal Res 2011; 50:328-335.
14. Reiter RJ, Tan DX, Poeggeler B et al. Melatonin as a free radical scavenger: implications for aging and age-related diseases. Ann N Y Acad Sci 1994; 719:1-12.
15. Tan DX, Chen LD, Poeggeler B et al. Melatonin: a potent endogenous hydroxyl radical scavenger. Endocr J 1993; 1:57-60.
16. Hill SM, Blask DE, Xiang S et al. Melatonin and associated signaling pathways that control normal breast epithelium and breast cancer. J Mammary Gland Biol Neoplasia 2011; 16:235-245.
17. Messina G, Lissoni P, Marchiori P et al. Enhancement of the efficacy of cancer chemotherapy by the pineal hormone melatonin and its relation with the psychospiritual status of cancer patients. J Res Med Sci 2010; 15:225-228.
18. Padillo FJ, Ruiz-Rabelo JF, Cruz A et al. Melatonin and celecoxib improve the outcomes in hamsters with experimental pancreatic cancer. J Pineal Res 2010; 49:264-270.
19. Grant SG, Melan MA, Latimer JJ et al. Melatonin and breast cancer: cellular mechanisms, clinical studies and future perspectives. Expert Rev Mol Med 2009; 11:e5.
20. Srinivasan V, Spence DW, Pandi-Perumal SR et al. Therapeutic actions of melatonin in cancer: possible mechanisms. Integr Cancer Ther 2008; 7:189-203.
21. Garcia-Navarro A, Gonzalez-Puga C, Escames G et al. Cellular mechanisms involved in the melatonin inhibition of HT-29 human colon cancer cell proliferation in culture. J Pineal Res 2007; 43:195-205.
22. Jung-Hynes B, Reiter RJ, Ahmad N. Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer. J Pineal Res 2010; 48:9-19.
23. Gonzalez A, del Castillo-Vaquero A, Miro-Moran A et al. Melatonin reduces pancreatic tumor cell viability by altering mitochondrial physiology. J Pineal Res 2011; 50: 250-260.
24. Um HJ, Park JW, Kwon TK. Melatonin sensitizes Caki renal cancer cells to kahweol-induced apoptosis through CHOPmediated up-regulation of PUMA. J Pineal Res 2011; 50: 359-366.
25. Mao L, Yuan L, Slakey LM et al. Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathway. Breast Cancer Res 2010; 12:R107.
26. Proietti S, Cucina A, Danselmi F et al. Melatonin and vitamin D3 synergistically down-regulate Akt and MDM2 leading to TGFbeta-1-dependent growth inhibition of breast cancer cells. J Pineal Res 2011; 50:150-158.
27. Martinez-Campa CM, onso-Gonzalez C, Mediavilla MD et al. Melatonin down-regulates hTERT expression induced by either natural estrogens (17beta-estradiol) or metalloestrogens (cadmium) in MCF-7 human breast cancer cells. Cancer Lett 2008; 268:272-277.
28. Dai M, Cui P, Yu M et al. Melatonin modulates the expression of VEGF and HIF-1 alpha induced by CoCl2 in cultured cancer cells. J Pineal Res 2008; 44:121-126.
29. Ram PT, Dai J, Yuan L et al. Involvement of the mt1 melatonin receptor in human breast cancer. Cancer Lett 2002; 179:141-150.
30. Blask DE, Hill SM, Dauchy RT et al. Circadian regulation of molecular, dietary, and metabolic signaling mechanisms of human breast cancer growth by the nocturnal melatonin signal and the consequences of its disruption by light at night. J Pineal Res 2011; 51:259-269.
31. Mao L, Cheng Q, Guardiola-Lemaitre B et al. In vitro and in vivo antitumor activity of melatonin receptor agonists. J Pineal Res 2010; 49:210-221.
32. Sinicrope FA, Gill S. Role of cyclooxygenase-2 in colorectal cancer. Cancer Metastasis Rev 2004; 23:63-75.
33. Singh B, Lucci A. Role of cyclooxygenase-2 in breast cancer. J Surg Res 2002; 108:173-179.
34. Kajita S, Ruebel KH, Casey MB et al. Role of COX-2, thromboxane A2 synthase, and prostaglandin I2 synthase in papillary thyroid carcinoma growth. Mod Pathol 2005; 18:221-227.
35. Kang CH, Chiang PH, Huang SC. Correlation of COX-2 expression in stromal cells with high stage, high grade, and poor prognosis in urothelial carcinoma of upper urinary tracts. Urology 2008; 72:153-157.
36. Sanborn R, Blanke CD. Cyclooxygenase-2 inhibition in colorectal cancer: boom or bust? Semin Oncol 2005; 32:69-75.
37. Lawlor MA, Alessi DR. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci 2001; 114:2903-2910.
38. Moroni MC, Hickman ES, Lazzerini DE et al. Apaf-1 is a transcriptional target for E2F and p53. Nat Cell Biol 2001; 3:552-558.
39. Kamarajan P, Sun NK, Sun CL et al. Apaf-1 overexpression partially overcomes apoptotic resistance in a cisplatin-selected HeLa cell line. FEBS Lett 2001; 505:206-212.
40. Srinivasula SM, Ahmad M, Fernandes-Alnemri T et al. Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol Cell 1998; 1:949-957.
41. Soengas MS, Alarcon RM, Yoshida H et al. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science 1999; 284:156-159.
42. Deng WG, Zhu Y, Montero A et al. Quantitative analysis of binding of transcription factor complex to biotinylated DNA probe by a streptavidin-agarose pulldown assay. Anal Biochem 2003; 323:12-18.
43. Deng WG, Zhu Y, Wu KK. Up-regulation of p300 binding and p50 acetylation in tumor necrosis factor-alpha-induced cyclooxygenase-2 promoter activation. J Biol Chem 2003; 278:4770-4777.
44. Deng WG, Tang ST, Tseng HP et al. Melatonin suppresses macrophage cyclooxygenase-2 and inducible nitric oxide synthase expression by inhibiting p52 acetylation and binding. Blood 2006; 108:518-524.
45. Xiao X, Shi D, Liu L et al. Quercetin suppresses cyclooxygenase-2 expression and angiogenesis through inactivation of P300 signaling. PLoS ONE 2011; 6:e22934.
46. Dubocovich ML. Luzindole (N-0774): a novel melatonin receptor antagonist. J Pharmacol Exp Ther 1988; 246: 902-910.
47. Cross DA, Alessi DR, Cohen P et al. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378:785-789.
48. Chlichlia K, Peter ME, Rocha M et al. Caspase activation is required for nitric oxide-mediated, CD95(APO-1/Fas)-dependent and independent apoptosis in human neoplastic lymphoid cells. Blood 1998; 91:4311-4320.
49. Malet G, Martin AG, Orzaez M et al. Small molecule inhibitors of Apaf-1-related caspase-3/-9 activation that control mitochondrial-dependent apoptosis. Cell Death Differ 2006; 13:1523-1532.
50. Zou H, Li Y, Liu X et al. An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 1999; 274:11549-11556.
51. Deng WG, Montero AJ, Wu KK. Interferon-gamma suppresses cyclooxygenase-2 promoter activity by inhibiting C-Jun and C/EBPbeta binding. Arterioscler Thromb Vasc Biol 2007; 27:1752-1759.
52. Persichini T, Maio N, di Patti MC et al. Interleukin-1beta induces ceruloplasmin and ferroportin-1 gene expression via MAP kinases and C/EBPbeta, AP-1, and NF-kappaB activation. Neurosci Lett 2010; 484:133-138.
53. Deng WG, Zhu Y, Wu KK. Role of p300 and PCAF in regulating cyclooxygenase-2 promoter activation by inflammatory mediators. Blood 2004; 103:2135-2142.
54. Yuan LW, Gambee JE. Histone acetylation by p300 is involved in CREB-mediated transcription on chromatin. Biochim Biophys Acta 2001; 1541:161-169.
55. Sarkar D, Su ZZ, Lebedeva IV et al. mda-7 (IL-24) Mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the GADD family of genes by means of p38 MAPK. Proc Natl Acad Sci U S A 2002; 99:10054-10059.
56. Bratton SB, Walker G, Srinivasula SM et al. Recruitment, activation and retention of caspases-9 and -3 by Apaf-1 apoptosome and associated XIAP complexes. EMBO J 2001; 20:998-1009.
57. Riedl SJ. Structure of the apoptotic protease-activating factor 1 bound to ADP. Nature 2005; 434:926-933.
58. Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 2004; 5:897-907.